Amgen/Takeda ASCO Data Could Help Guide Vectibix Use In mCRC
Executive Summary
The PARADIGM study took place in Japan, but it was described as the first to prospectively evaluate treatment of wild-type RAS mCRC and left-sided primary tumors.
You may also be interested in...
Amgen’s Q1 Overshadowed By Tax Dispute That May Cost $7.1bn To Resolve
First quarter revenue of $6.2bn and product sales of $5.7bn were up 6% and 2%, respectively, year over year. However, a looming – and potentially growing – tax liability is a multibillion-dollar overhang.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.